Vitamin D Supplementation Among Pregnant Women in Uganda for the Prevention of Hypertensive Disorders in Pregnancy, and Other Adverse Maternal and Foetal Outcomes

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18+
SponsorSt Mary's Hospital, Lacor

About this trial

The goal of this randomised controlled trial is to investigate if vitamin D supplementation among pregnant women in Uganda prevents adverse maternal and foetal outcomes, with special emphasis on preeclampsia.

The main question it aims to answer is if Vitamin D supplementation, administered as oral vitamin D₃ at a dose of 2,000 IU once daily, from the time of recruitment to the time of delivery, reduces the incidence of preeclampsia, eclampsia and HELLP syndrome in pregnant women attending ANC at St. Mary's Hospital, Lacor, such incidence being monitored up to six (6) weeks after delivery.

Researchers will compare the effect of oral 2.000 IU vitamin D daily (intervention group) vs. oral placebo daily (control group) on the prevalence of adverse maternal and foetal outcomes.

Eligibility criteria

Qualifiers

with a viable intrauterine pregnancy,

at gestational age at recruitment between 13 weeks 0 days and 27 weeks 6 days, and

who consented to participate in the study.

Disqualifiers

women already on Vitamin D treatment prescribed by a physician.

Trial design

Treatments tested in this trial

  • oral 2.000 IU vitamin D3 (cholecalciferol) daily, in addition to routine ANC supplementations
  • Placebo

Treatment groups

1,980 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

St Mary's Hospital, Lacor

Lead sponsor

University of Naples

Collaborator